A "cookie" is a small file that is places on the disk of your device (computer, phone, tablet) by a website. The main function of a cookie is to differentiate one user from another. You'll often see cookies on sites where a login is required. A cookie will keep you logged in while using the site.
If you want to find out more, check this excellent explanation of the Consumentenbond (in Dutch).
This site uses cookies (and similar technologies) to save your preferences, so that we can offer a personalised, thus better, experience. The information that is saved in these cookies is encrypted and can only be read (again) by this website. And this, only when you are active on the site.
At the moment, we use the following cookies:
The first two cookies are essential cookies (to protect forms and to keep session information for logged in users), for which we don't need your permission. The last cookie is only saved when a user chooses for this option.
We don't use cookies of third parties (like Google Analytics of Facebook,…). Because we don't have an impact on the reach of their cookie policy statements, nor on the concrete content of their cookies.
As a result of the GDPR legislation, websites from the EU are obliged to provide information about the cookies used and request permission when a non-essential cookie is placed on your disk. This policy informs you clearly (and completely) about which cookies we use and why we do this.
Since we do not use non-essential cookies, you will not see a cookie banner to enter preferences.
Also be aware that you can always adjust your browser settings if you prefer to refuse certain cookies. Keep in mind that this can lead to a less good user experience.
Below you can find the information about cookie settings in the most commonly used browsers:
- Cookie settings in Google Chrome
- Cookie settings in Apple’s Safari
- Cookie settings in Mozilla Firefox
- Cookie settings in Opera
Additionally, you can resolutely block all cookies by ticking the settings for refusing cookies in your browser. However, if you do this, it will result in you no longer being able to use the website.
If you still have a question (or suggestion) related to our cookie policy, don't hesitate to send an e-mail to info@ncpflanders.be.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.